1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | KASUMI-1; Kasumi 1; KASUMI1; Kasumi1 |
| Species | Human |
| Cat.No | ABC-TC0492 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Myeloblast |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Acute Myeloid Leukemia |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
Kasumi-1 is a human acute myeloid leukemia (AML) cell line established from the peripheral blood of a 7-year-old Japanese male patient with relapsed AML (FAB M2 subtype) following bone marrow transplantation. This suspension-growing cell line exhibits myeloblast-like morphology and carries t(8;21)(q22;q22) translocation. Kasumi-1 cells express myeloid surface makers such as CD34, CD33, CD13, CD15, and HLA-DR. They respond to interleukin-3 (IL-3), IL-6, granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage CSF (GM-CSF), but not to IL-1 or IL-5. The cell line is sensitive to phorbol ester-induced macrophage differentiation and demonstrates tumorigenic potential in xenograft model. These features position Kasumi-1 as a critical model for studying AML pathogenesis and therapeutic interventions targeting fusion oncoproteins.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
The Kasumi-1 cell line serve as a critical model for investigating the molecular and cellular mechanisms nderlying acute myeloid leukemia (AML) with t(8;21) translocation. They are extensively used in research on core-binding factor (CBF) leukemias, particularly for studying dysregulated KIT signaling, which frequently co-occurs with this translocation. Kasumi-1 cells support a wider range of applications, including 3D cell culture, immunology and hematopoietic disorder studies, and preclinical drug screening. Furthermore, their well-characterized genetic profile and reliable cytokine responsiveness make them a valuable tool for dissecting AML pathophysiology and testing targeted therapeutic strategies.
